Scarica l'app Stockscreener
33.77
3.51%
-1.23
Dopo l'orario di chiusura:
33.77
Immunocore Holdings Plc Adr Borsa (IMCR) Ultime notizie
How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak - Yahoo! Finance Canada
Is Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth? - TradingView
Immunocore's Kimmtrak Growth Story and Major 2026 Catalysts Ahead - TradingView
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma - TradingView
PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare - TradingView
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why - TradingView
IMCR News | IMMUNOCORE HOLDINGS PLC-ADR (NASDAQ:IMCR) - ChartMill
Is it a good idea to invest in Immunocore stock right now? - MSN
Here's Why You Should Add Kiniksa Stock to Your Portfolio Now - TradingView
Here's Why You Should Add ANIX Stock to Your Portfolio Now - TradingView
Reasons Why Investors Should Consider Betting on Indivior Stock - TradingView
RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib - TradingView
NVO Gains as Foundation Unveils EUR 60M Cardiometabolic Research Push - TradingView
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria - TradingView
PFE Stock Slides Following CFO Exit, 2026 Guidance Reaffirmed - TradingView
JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies - TradingView
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It? - TradingView
Is it a Good Idea to Invest in Immunocore Stock Right Now? - TradingView
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised) - TradingView
NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up - TradingView
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure - TradingView
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review - TradingView
INDV Stock: What Sublocade Growth Signals for 2026 - TradingView
GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorder - TradingView
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why - TradingView
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US - TradingView
Sanofi Ends Late-Stage Study on Neurology Drug Over Weak Results - TradingView
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs - TradingView
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week? - TradingView
Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know - TradingView
ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data - TradingView
Amgen Secures EU Nod for Imdylltra in Lung Cancer Indication - TradingView
MRNA Partners With CEPI to Develop Vaccine for Bundibugyo Ebolavirus - TradingView
REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug - TradingView
AGIO Halts Tebapivat Development in Myelodysplastic Syndromes - TradingView
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma - GlobeNewswire Inc.
Immunocore reports Phase 1 data for melanoma drug brenetafusp - Investing.com
TGTX's Single-Dose Briumvi Hits Bioequivalence Goal in MS Study - TradingView
Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy - TradingView
IMCRImmunocore Holdings plc ADR Stock Price and Quote - Finviz
AGIO's Pyrukynd Gets Approval for Thalassemia in Europe - TradingView
Wall Street analysts think Immunocore (IMCR) could surge 111.53%: Read this before placing a bet - MSN
69,271 ADRs sale scheduled by Immunocore (NASDAQ: IMCR) - Stock Titan
Here's Why You Should Add Altimmune Stock to Your Portfolio Now - TradingView
Wall Street Analysts Think Immunocore (IMCR) Could Surge 111.53%: Read This Before Placing a Bet - Yahoo Finance
Immunocore Holdings (NASDAQ: IMCR) plans 65,000 ADR cashless sale - Stock Titan
Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients - TradingView
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now? - TradingView
ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know - TradingView
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know - TradingView
BMRN Stock Down on Mixed Results From Rare Disease Therapy Study - TradingView
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy - TradingView
Bayer Gets FDA Priority Review for Asundexian NDA in Stroke Prevention - TradingView
Roche's Tecentriq Wins FDA Nod for Label Expansion in Bladder Cancer - TradingView
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised - TradingView
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):